Answers are grounded in this paper and cite their sources.
Ipilimumab, an immune checkpoint inhibitor, is approved for the treatment of advanced melanoma. Its potential activity in keratinocytic cancers, however, is not well known. We present a case of a man in his 60s with advanced basal cell carcinoma (BCC) that regressed after incidental exposure to ipilimumab to treat the patient's concurrent metastatic melanoma.
No takes yet. Share an insight, caveat, or question.
Mohan et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: